Everest Medicines announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes”. Everest Medicines acquired the rights to develop, manufacture, and commercialize CARDAMYST(R) (etripamil), a treatment for acute PSVT episodes, in Greater China (including Mainland China, Hong Kong, Macao and Taiwan) in March 2026.
CARDAMYST(R) (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST(R) is currently the only self-administered treatment for adults with PSVT to treat episodes rapidly. The drug was approved by China's National Medical Products Administration (NMPA) in September 2026 for converting acute symptomatic episodes of paroxysmal PSVT to sinus rhythm in adults.
According to clinical data, treatment effects can be observed as early as five minutes after administration, with 64 per cent of patients achieving conversion to sinus rhythm within 30 minutes and a median time to conversion of 17 minutes. CARDAMYST(R) was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits.
Positioned as an on-demand treatment that enables patients to take control of their heart rhythm, CARDAMYST(R) empowers patients with PSVT to better manage their condition and their lives. It has the potential to transform the treatment paradigm for acute PSVT episodes from passive emergency care in hospitals to proactive self-management by patients, helping to alleviate anxiety during episodes, reduce emergency department visits and disease burden, and further improve long-term disease management and quality of life.
Research presented at ESC Congress 2026 shows that PSVT is a chronic condition that continues to impact patients’ quality of life, rather than simply an occasional acute emergency. Patients with PSVT experience a substantial burden between episodes, with negative impacts on anxiety, daily activities, sleep, and work. Therefore, beyond acute treatment and subsequent catheter ablation, ensuring timely and convenient treatment during an episode is also an important aspect of PSVT management.
